A Brashear

Summary

Affiliation: Indiana University
Country: USA

Publications

  1. doi Use of botulinum toxin type A in poststroke spasticity
    Allison Brashear
    Indiana University School of Medicine, 550 University Blvd, Rm 6620, Indianapolis, IN 46202, USA
    Expert Rev Neurother 3:271-7. 2003
  2. ncbi Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial
    Allison Brashear
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Arch Phys Med Rehabil 85:705-9. 2004
  3. ncbi Treatment with botulinum toxin type B for upper-limb spasticity
    Allison Brashear
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202 5250, USA
    Arch Phys Med Rehabil 84:103-7. 2003
  4. ncbi Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity
    Allison Brashear
    Indiana University School of Medicine, Indianapolis, IN, USA
    Arch Phys Med Rehabil 83:1349-54. 2002
  5. ncbi Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke
    Allison Brashear
    Department of Neurology, Indiana University School of Medicine, Indianapolis 46202, USA
    N Engl J Med 347:395-400. 2002
  6. ncbi Botulinum toxin type B: a new injectable treatment for cervical dystonia
    A Brashear
    Indiana University School of Medicine, Department of Neurology, 550 University Boulevard, Room 6620, Indianapolis, IN 46202 5250, USA
    Expert Opin Investig Drugs 10:2191-9. 2001
  7. ncbi The safety and tolerability of botulinum toxins for the treatment of cervical dystonia
    Allison Brashear
    Indiana University Medical Center, Department of Neurology, CL 291, Indianapolis, IN 46202 5250, USA
    Expert Opin Drug Saf 4:241-9. 2005
  8. ncbi The botulinum toxins in the treatment of cervical dystonia
    A Brashear
    Department of Neurology, Indiana University Medical Center, Indianapolis 46202-5250, USA
    Semin Neurol 21:85-90. 2001
  9. doi Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
    D M Simpson
    Department of Neurology, Mount Sinai Medical Center, New York, NY, USA
    Neurology 70:1699-706. 2008
  10. ncbi Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia
    J Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
    Neurology 67:2233-5. 2006

Collaborators

Detail Information

Publications17

  1. doi Use of botulinum toxin type A in poststroke spasticity
    Allison Brashear
    Indiana University School of Medicine, 550 University Blvd, Rm 6620, Indianapolis, IN 46202, USA
    Expert Rev Neurother 3:271-7. 2003
    ..Side effects of the injections were mild and self-limited. Botulinum toxin type A injections for upper extremity spasticity are safe and efficacious, and should be considered as first choice in the treatment of this disorder...
  2. ncbi Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial
    Allison Brashear
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Arch Phys Med Rehabil 85:705-9. 2004
    ..To determine whether botulinum toxin type B (BTX-B) is effective in controlling upper-limb spasticity...
  3. ncbi Treatment with botulinum toxin type B for upper-limb spasticity
    Allison Brashear
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202 5250, USA
    Arch Phys Med Rehabil 84:103-7. 2003
    ..To determine if botulinum toxin type B (MyoBloc) decreases spasticity...
  4. ncbi Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity
    Allison Brashear
    Indiana University School of Medicine, Indianapolis, IN, USA
    Arch Phys Med Rehabil 83:1349-54. 2002
    ..To evaluate the reliability of the Ashworth Scale and the Disability Assessment Scale (DAS) in poststroke patients with upper-limb spasticity and functional disability...
  5. ncbi Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke
    Allison Brashear
    Department of Neurology, Indiana University School of Medicine, Indianapolis 46202, USA
    N Engl J Med 347:395-400. 2002
    ..Spasticity is a disabling complication of stroke, and it is uncertain whether intramuscular injections of botulinum toxin type A reduce disability in persons with spasticity of the wrist and fingers after a stroke...
  6. ncbi Botulinum toxin type B: a new injectable treatment for cervical dystonia
    A Brashear
    Indiana University School of Medicine, Department of Neurology, 550 University Boulevard, Room 6620, Indianapolis, IN 46202 5250, USA
    Expert Opin Investig Drugs 10:2191-9. 2001
    ..Benefits were noted both in patients who no longer respond and in those who continue to respond to botulinum toxin type A (BTX-A). BTX-B offers an additional therapeutic option for patients with CD...
  7. ncbi The safety and tolerability of botulinum toxins for the treatment of cervical dystonia
    Allison Brashear
    Indiana University Medical Center, Department of Neurology, CL 291, Indianapolis, IN 46202 5250, USA
    Expert Opin Drug Saf 4:241-9. 2005
    ....
  8. ncbi The botulinum toxins in the treatment of cervical dystonia
    A Brashear
    Department of Neurology, Indiana University Medical Center, Indianapolis 46202-5250, USA
    Semin Neurol 21:85-90. 2001
    ..The potential availability of both forms of toxin will allow physicians to offer further treatment options to patients with CD...
  9. doi Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
    D M Simpson
    Department of Neurology, Mount Sinai Medical Center, New York, NY, USA
    Neurology 70:1699-706. 2008
    ..To perform an evidence-based review of the safety and efficacy of botulinum neurotoxin (BoNT) in the treatment of movement disorders...
  10. ncbi Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia
    J Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
    Neurology 67:2233-5. 2006
    ..One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy...
  11. ncbi Rapid-onset dystonia-parkinsonism: linkage to chromosome 19q13
    P L Kramer
    Department of Neurology, Oregon Health Sciences University, Portland 97201, USA
    Ann Neurol 46:176-82. 1999
    ..Identification of the genetic defect in RDP holds promise for understanding the underlying disease processes of both of these more common diseases...
  12. ncbi Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia
    Allison Brashear
    Department of Neurology, Indiana University Medical Center, 550 University Boulevard, Room 6620, Indianapolis, IN 46202, USA
    Adv Ther 22:49-55. 2005
    ..48 days during the first year of observation and 114.14 days during the second year. These findings indicate that doses of and intervals between BoNT/A treatments for cervical dystonia were consistent throughout 2 years of observation...
  13. ncbi Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials
    Stuart A Yablon
    Brain Injury Program, Methodist Rehabilitation Center, Jackson, Mississippi 39216, USA
    Clin Ther 29:683-90. 2007
    ..The purpose of this study was to investigate the incidence of neutralizing antibody (NAb) formation in patients with poststroke spasticity treated with a specific formulation of botulinum toxin type A (BoNTA)...
  14. doi Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients
    Elie P Elovic
    Kessler Medical Rehabilitation Research and Education Center, West Orange, NJ, USA
    Arch Phys Med Rehabil 89:799-806. 2008
    ....
  15. ncbi Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke
    Martin K Childers
    Dept of Physical Medicine and Rehabilitation, University of Missouri at Columbia, One Hospital Drive, DCO 46 00, Columbia, MO 65212, USA
    Arch Phys Med Rehabil 85:1063-9. 2004
    ..To test the hypothesis that intramuscular (IM) botulinum toxin type A (BTX) reduces excessive muscle tone in a dose-dependent manner in the elbow, wrist, and fingers of patients who experience spasticity after a stroke...
  16. doi Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay
    Mitchell F Brin
    Allergan, Inc, Global Drug Development, Irvine, California, USA
    Mov Disord 23:1353-60. 2008
    ..The current formulation of BoNTA rarely causes neutralizing antibody formation in CD subjects treated < or =4 years...
  17. ncbi Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia
    Karmen K Yoder
    Department of Radiology, Division of Research, Section of Imaging Science, 950 W Walnut St, Research Institute 2, Room E124, Indianapolis, IN 46202, USA
    Schizophr Res 71:371-5. 2004
    ..Significant and trend-level inverse correlations were found between DAT BP in the striatum, and especially the severity of negative symptom scores, but also cognitive, and depression/anxiety scores on the PANSS...